HIV Science

Closed
Curso
en
Inglês
Subtitles available
6 h
Este conteúdo é classificado como 0 de 5
Fonte
  • De www.fun-mooc.fr
CONDIÇÕES
  • Acesso livre
  • Certificado gratuito
Mais informações
  • 30 sequências
  • Intermediate Level
  • Legendas em English, French
  • Começa em 1 novembro 2018
  • Termina em 20 dezembro 2018

Their employees are learning daily with Edflex

  • Safran
  • Air France
  • TotalEnergies
  • Generali
Saiba mais

Detalhes do curso

Programa de Estudos

Chapter 1 : Origin, Epidemiology and natural history of HIV infection/ Origine, épidémiologie et histoire naturelle de l’infection par VIH

  • Discovery of the etiological agent of AIDS/Découverte de l’agent étiologique du SIDA
  • Origin of HIV and animal reservoirs/Origine du VIH et réservoirs animaux
  • Modes of transmission and natural history of infection/Mode de transmission et histoire naturelle de l’infection.
  • Epidemiology of HIV and AIDS in the world/Epidémiologie du VIH et du SIDA à travers le monde
  • Types, groups, subtypes and recombinants of HIV in the world/Types, groupes, sous-types et recombinants du VIH à travers le monde.

Chapter 2: Mechanisms of HIV replication and dissemination. The establishment of viral reservoirs./Mécanismes de réplication virale et de dissémination. La formation de réservoirs viraux.

  • First steps of viral entry in the body. Mucosae: the entry gate./ Premières étapes de l’entrée du virus dans l’organisme. Les muqueuses : la porte d’entrée.
  • Cellular targets and mechanisms of viral dissemination from cell to cell./ Cibles cellulaires et mécanismes de la dissémination virale entre les cellules.
  • Replication cycle: facilitating and restriction factors. / Cycle de réplication du virus : facteurs de facilitation et de restriction.
  • HIV transcription and latency. / Transcription du virus et latence.
  • Cellular and anatomical reservoirs. Viral persistence on cART. / Réservoirs cellulaires et anatomiques. Persistance du virus sous chimiothérapie antirétrovirale.

Chapter 3 : HIV and the immune system. / VIH et immunité.

  • Innate immune responses: viral sensing and dendritic cells. / Immunité innée: détection virale et cellules dendritiques.
  • Innate immune responses : NK cells. / Immunité innée : cellules NK
  • Adaptive immune responses : T-cell responses. / Immunité adaptative : la réponse cellulaire T.
  • Adaptive immune responses : B-cell responses and antibodies. / Immunité adaptative : Réponse cellulaire B et anticorps.
  • Immune evasion: from escape to viral neglect. / Evasion : de l’échappement à la négligence.

Chapter 4: Physiopathology of HIV infection/ Physiopathologie de l’infection à VIH.

  • Mechanisms of HIV-induced pathogenesis: inflammation, disruption of lymphoid tissue architectures, premature aging. / Mécanismes des modifications induites par le VIH : perturbations de l’architecture du tissu lymphatique, vieillissement prématuré.
  • HIV and co-infections. / VIH et coïnfections.
  • Natural control of pathogenesis in natural hosts. / Contrôle naturel des modifications chez l’hôte.
  • Exposed non-infected individuals. / Individus exposés mais non infectés.
  • Natural control of infection and HIV remission. / Contrôle naturel de l’infection et rémission de la maladie VIH.

Chapter 5 : Clinical management./ Prise en charge clinique.

  • Diagnostic methods. / Méthodes diagnostiques.
  • Anti-retroviral therapies. / Thérapies antirétrovirales.
  • Biomarkers of disease progression and loss of viral control. / Les biomarqueurs de progression et de perte de contrôle de la maladie.
  • Anti-retroviral resistance. / Résistance aux anti-rétroviraux.
  • Impact of long-term HIV infection on cART: Co-morbidity and non-AIDS mortality./ Impact de l’infection au VIH à long terme sur la trithérapie : comorbidité et mortalité non liée au SIDA.

Chapter 6 : Perspectives and future challenges. / Perspectives et challenges.

  • The antiretroviral treatment tomorrow. / Le traitement antirétroviral de demain.
  • Treatment as prevention (PreP, PEP and TASP). / Les traitements préventifs (PreP, PEP et TASP)
  • Vaccines, what is there in the pipeline? / Vaccination : quelles sont les perspectives ?
  • Perspectives to achieve HIV remission or cure. / Sera-t-il possible d’envisager la rémission ou la guérison ?
  • What do PLWH expect next from research? / Qu’attendent les porteurs actuels du VIH des progrès de la recherche ?

Pré-requisito

TWe recommend a good scientific background (such as a bachelor of science)./ Un bon niveau scientifique est recommandé pour suivre ce MOOC (licence en sciences).

Instrutores

Michaela Müller-Trutwin
Michaela Müller-Trutwin is Associate Professor and the head of the “HIV, Inflammation and Persistence” Unit at Institut Pasteur, where she also directed the international PhD program. She is the President of the Coordinated Action on HIV Basic research at the ANRS and Vice-President of the Scientific Council at Institut Pasteur. Her work is focused on identifying factors involved in the protection against chronic inflammation and the control of viral reservoirs with the aim to translate the findings into clinical research.

Asier Sáez-Cirión
Asier Sáez-Cirión is Associate Professor at Institut Pasteur and Team Leader at the HIV, Inflammation and Persistence Unit. He is the Co-coordinator of the ANRS RHIVIERA consortium on HIV remission and the ANRS VISCONTI study. He is the president of the scientific and medical committee of Sidaction. His work is currently focused on understanding natural mechanisms associated with control of HIV/SIV infection and progression to AIDS. In particular he studies the role of intrinsic and adaptive immunity and the impact of viral reservoirs in different models of spontaneous or induced control of viremia in the absence of antiretroviral therapy.

Editor

O Institut Pasteur é uma fundação francesa privada, sem fins lucrativos, com sede em Paris, dedicada ao estudo da biologia, dos microrganismos, das doenças e das vacinas.

Criado em 1888 graças a uma subscrição pública internacional, tem o nome de Louis Pasteur1, o seu fundador e primeiro diretor, que em 1885 desenvolveu a primeira vacina contra a raiva.

Durante mais de um século, o Instituto Pasteur esteve na vanguarda da luta contra as doenças infecciosas. Em 1983, este organismo internacional de investigação foi o primeiro a isolar o vírus da imunodeficiência humana (VIH), o vírus que causa a síndrome da imunodeficiência adquirida (SIDA). Ao longo dos anos, foi responsável por descobertas revolucionárias que permitiram à medicina controlar doenças virulentas como a difteria, o tétano, a tuberculose, a poliomielite, a gripe, a febre amarela, a peste epidémica, a hepatite B e a SIDA.

Plataforma

France Université Numérique est le diffuseur des cours en ligne des établissements d’enseignement supérieur français et de leurs partenaires.

Il opère plusieurs plateformes de diffusion, dont la plus connue, FUN MOOC, est la première plateforme académique francophone mondiale. Grâce à de nombreux établissements partenaires, cette plateforme propose un vaste catalogue de cours s’enrichissant de jour en jour avec des thématiques variées et d’actualité.
 

Este conteúdo é classificado como 4.5 de 5
(nenhuma revisão)
Este conteúdo é classificado como 4.5 de 5
(nenhuma revisão)
Conclua este recurso para fazer uma avaliação